Skip to content
Biohaven Ltd old icon

Biohaven Ltd old

BHVNoldStocksPharmaceuticals MajorUnited StatesNYSEUSD

Price

$15.40

Today

-0.8%

YTD

+0.0%

About

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company that develops product candidates to treat neurological diseases and rare disorders. Operating in the United States and incorporated in 2013, Biohaven Pharmaceutical has its headquarters in New Haven, Connecticut. As of November 2021, Biohaven Pharmaceutical has a range of product candidates that are undergoing clinical testing, in addition to one product that has received approval for treatment in the United States. NURTEC ODT (rimegepant) has been approved for the acute treatment of migraines as well as for preventative treatment of migraines. Zavegepant is currently in phase III clinical trials for acute and preventative treatment of migraines, in addition to being tested for treatment of respiratory complications of Covid-19. The company also has Troriluzole in phase III clinical trials for the treatment of spinocerebellar ataxia (SCA) and obsessive-compulsive disorders (OCD). Verdiperstat is in phase III clinical trials for treating amyotrophic lateral sclerosis (ALS). Biohaven Pharmaceutical stock is listed on the NYSE under the ticker BHVN. The company has a collaborative agreement with Cove to facilitate telemedicine evaluation for those who suffer from migraines. In January 2021, Biohaven Pharmaceutical announced that it had acquired the remaining interest in Kleo Pharmaceuticals that it did not previously own. Keep an eye on the price movements of BHVN stock by adding it to your eToro watchlist.

Price chart
Closing price history for BHVNold (1D candles).
Open positions
Current open positions for this instrument from your live portfolio.

Open positions

0

Unrealized return

+0.0%

No open positions exist for this instrument at the moment.

Financial insights

Valuation

P/E (TTM)-3.21
P/S (TTM)0.00
P/B (TTM)-19.05
Market cap$1.87B
Cap tierSmall-cap
Industry avg P/E-17.91

Profitability

Gross marginUnknown
EBIT margin0.00%
Net marginUnknown
ROE-799.46%
ROA-161.32%

Earnings & Revenue

Revenue (TTM)$0.00
Revenue growth (1Y)Unknown
EPS (TTM)-$3.86
Free cash flow$-473.17M
Total debt$300.44M

Dividends & Risk

Dividend rate$0.00
Dividend yield0.00%
Beta (5Y)1.56
Employees274
Next earnings10 Nov '25
Trade history

Closed trades

0

Realized return

+0.0%

No stored closed trades exist for this instrument yet.